Nutriband Inc. — Form 10-K Summary
Reporting period: Fiscal year ended January 31, 2018. Although the request metadata refers to 2017 Q4, this filing reports the full fiscal year and compares it with the year ended January 31, 2017. The company develops transdermal consumer products and prescription-drug candidates; it reported no significant consumer-product sales and no pharmaceutical sales.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $2,671,946 | $151,260 |
| Selling, general and administrative expense | $171,946 | $151,260 |
| Cash used in operating activities | $92,858 | $147,923 |
| Cash and cash equivalents at year-end | $0 | $27,124 |
- The 2018 loss included a $2.5 million impairment charge that reduced the carrying value of patents acquired from Advanced Health Brands to zero. The patents were provisional, and the company reported no income or cash flow from their use.
- At January 31, 2018, total assets were $164,899, current liabilities were $43,391, and stockholders’ equity was $121,508. Current assets were $164,899, including $160,503 in prepaid expenses; working capital was therefore $121,508.
- Debt included $14,230 due to related parties and a $1,820 council loan balance reported as in default, plus a $15,000 interest-free loan due on demand. The filing’s balance sheet reports total notes payable of $16,820.
- Accumulated deficit was $2,849,410. The company had 20,877,100 common shares outstanding at January 31, 2018. The filing reports no dividends and no off-balance-sheet arrangements.
Changes and notable developments
- Revenue remained zero, while net loss increased substantially from the prior year, principally because of the $2.5 million patent impairment. SG&A rose by $20,686, mainly due to higher legal fees.
- In May 2017, the company acquired Advanced Health Brands’ transdermal patent rights for 5 million shares valued at $2.5 million; the entire recorded value was impaired by year-end.
- In September 2017, the company rescinded its acquisition of Edgemark Innovation after due diligence raised concerns about financial transparency; the parties instead restructured a mutual distribution arrangement.
- After year-end, on April 5, 2018, the company agreed to acquire 4P Therapeutics for $400,000 and 250,000 shares, contingent on completion of a certified audit. The filing describes 4P as a clinical-development arm. Other post-period events include the February 2018 appointment of Sean Gallagher as president.
- Financing during FY 2018 included $50,000 from common-stock sales and $15,000 in short-term debt. The company also issued 5 million shares for the patent acquisition and 215,000 shares for services.
Liquidity, outlook, risks, and controls
- Going concern: Management and the auditor identify substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, no revenue, cash used in operations, and the need for additional funding. The auditor issued an unmodified opinion on the financial statements with a going-concern explanatory paragraph.
- Funding needs: Management estimated next-12-month operating expenses of at least $1.5 million and separately estimated product development and marketing capital requirements of $500,000 to $1.5 million. It had no committed financing arrangements and said failure to raise funds could threaten viability.
- Business and regulatory risks: Prescription candidates remain in development, with no assurance of clinical success or FDA approval; management said substantial capital would be needed to advance the pipeline. The company disclosed no internal product studies beyond a manufacturer-provided caffeine skin-flow test and said it had not conducted further testing.
- Operations: Consumer products depend substantially on one contract manufacturer. The company had a quality-control agreement but no formal manufacturing agreement governing key commercial terms. The manufacturer did not have an FDA CGMP certificate; the company said the manufacturer represented that its facility complied with applicable requirements.
- Other risks: Limited operating history, market acceptance and competition, dependence on the CEO and other key personnel, potential dilution from future fundraising, litigation and regulatory exposure, and cybersecurity risks.
- Internal controls: Management concluded disclosure controls and internal control over financial reporting were ineffective as of January 31, 2018 because of a lack of segregation of duties. The auditor did not attest to internal-control effectiveness.
- Outlook: No revenue or earnings guidance was provided. Management expressed expectations that proposed acquisitions could be profitable and help fund operations, but these expectations were uncertain.
Important facts for investors to verify
- Current cash, subsequent financing, and the company’s ability to meet the stated funding requirements and continue as a going concern.
- Status, ownership, validity, and development plans for the provisional Advanced Health Brands patents after the full impairment.
- Completion and terms of the 4P Therapeutics acquisition, including audit conditions, consideration, liabilities, and clinical-pipeline status.
- Status of the defaulted council loan and other debt, including the related-party advances due on demand.
- Whether a formal manufacturing agreement was executed and whether manufacturing, product testing, and regulatory compliance support commercial claims.
- Remediation of the disclosed control deficiencies and progress toward revenue, clinical milestones, and regulatory approvals.